VivoSeq
Other

Durvalumab

0

Pipeline Programs↗

10

Active Trials↗

3

Companies Involved↗

Durvalumab is an early-stage landscape with 0 programs across 3 companies. The most active players are AstraZeneca, Mario Negri Institute for Pharmacological Research, Jazz Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

57/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

0 programs

PreclinicalMario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research

0 programs

PreclinicalJazz Pharmaceuticals logo

Jazz Pharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

20

clinical trials

Active, not recruiting5 · 25%
Completed4 · 20%
Unknown status3 · 15%
Withdrawn3 · 15%
Recruiting3 · 15%
Not yet recruiting2 · 10%

Clinical Trials

Trial Activity

20 trials

FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum
Recruiting·CCentre Leon Berard·Phase 2·NCT06393816·80 enrolled
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
Recruiting·—·Phase 2·NCT05655949·30 enrolled
WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC
Recruiting·AAGO Research GmbH·Phase 2·NCT04644289·60 enrolled
BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants
Active, not recruiting·AstraZeneca logoAstraZeneca·Phase 3·NCT05943106·100 enrolled
1st Line Durvalumab in PS 2 NSCLC Patients
Active, not recruiting·SSwiss Cancer Institute·Phase 2·NCT03620669·48 enrolled
Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN
Active, not recruiting·GGroupe Oncologie Radiotherapie Tete et Cou·Phase 2·NCT03726775·61 enrolled
Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28)
Active, not recruiting·AAssociation NVALT Studies·Phase 3·NCT04597671·170 enrolled
A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1)
Active, not recruiting·National Cancer Institute, Naples·Phase 1·NCT06218511·10 enrolled
Durvalumab as Consolidation for Patients LS-SCLC
Not yet recruiting·—·Phase 2·NCT07055581·100 enrolled
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
Not yet recruiting·Jazz Pharmaceuticals logoJazz Pharmaceuticals·Phase 2·NCT07459634·50 enrolled
A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.
Completed·AstraZeneca logoAstraZeneca·Phase 2·NCT04495179·30 enrolled
Diadem to Investigate the Activity and Safety of Durvalumab
Completed·Mario Negri Institute for Pharmacological Research logoMario Negri Institute for Pharmacological Research·Phase 2·NCT04115111·57 enrolled
Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC
Completed·AstraZeneca logoAstraZeneca·Phase 2·NCT03822351·189 enrolled
PD-L1 ImagiNg to prediCt Durvalumab Treatment Response in HNSCC
Completed·RRadboud University Medical Center·Phase 1/2·NCT03829007·33 enrolled
Durvalumab in DLBCL After Autologous Transplant
Withdrawn·IInsel Gruppe AG, University Hospital Bern·Phase 2·NCT03241017
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)